



Executive Summary of Joint Working Outputs
 Published on www.bayer.co.uk

| | |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Project Title | Bucks and Berks AF Stroke Prevention Programme |
| Duration | January 2017 to June 2018 |
| Project Partners | Oxford Academic Health Science Network Bayer plc |
| What was the issue to be addressed? | A primary care quality improvement project aimed at developing the management of atrial fibrillation patients across Buckinghamshire and Berkshire |
| What was the intervention? | <ul style="list-style-type: none"> • The project involved a pharmacist-led data review of patients with known AF at GP Practices across Buckinghamshire and Berkshire. The aim was to identify those at high risk of stroke and either not anticoagulated or not adequately anticoagulated. • Implementation of a quality improvement (QI) project involving a consultation review and provision of optimal treatment for identified patients to produce improvements in outcomes. • Creation of a Quality Improvement Support Team to facilitate the creation of a patient review pathway and leave a legacy of transferable QI expertise in participating practices. |
| What were the results? | <ul style="list-style-type: none"> • Over the duration of the project: <ul style="list-style-type: none"> ○ 280 patients (88% of patients assessed as being ‘high risk’) prescribed oral anticoagulant therapy ○ Anticoagulation optimised in an additional 520 patients |

